MedTrace Logo

Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection

NCT05872659 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-05-24

No results posted yet for this study

Summary

The goal of this clinical trial is to explore the effect of mesenchymal stem cell therapy on immune non-responder patients. The main questions it aims to answer are:

1. Efficacy of human umbilical cord mesenchymal stem cells combined with antiviral therapy in the treatment of AIDS patients with immune non-response.
2. Safety of human umbilical cord mesenchymal stem cells combined with antiviral therapy in AIDS patients with immune non-response.

Participants will receive CD4,CD4/CD8, and RNA viral load tests and will be randomly assigned to either saline or mesenchymal stem cell therapy.

Investigators will evaluate the safety and efficacy of mesenchymal stem cell therapy based on examination results.

Conditions

  • AIDS Virus
  • Disorder of Immune Reconstitution

Interventions

OTHER

normal saline

iv at D0, D30, D60

BIOLOGICAL

Mesenchymal stem cells

iv at D0, D30, D60

Sponsors & Collaborators

  • Shandong Public Health Clinical Center

    collaborator OTHER_GOV

  • Shandong Qilu Cell Therapy Engineering Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Chenfan liu · Shandong Public Health Clinical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-16
Primary Completion
2025-11-15
Completion
2025-11-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05872659 on ClinicalTrials.gov